Labcorp Appoints Johnson & Johnson Executive Kathryn Wengel to the Board of Directors
March 26 2021 - 6:57AM
Business Wire
Healthcare Veteran Brings Significant Global
Industry Experience
Labcorp (NYSE: LH), a leading global life sciences company,
today announced the appointment of Kathryn Wengel, current
Executive Vice President and Chief Global Supply Chain Officer at
Johnson & Johnson, as an independent member of Labcorp’s Board
of Directors, effective immediately. In connection with this
appointment, the Labcorp Board will expand from 9 to 10
directors.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210326005182/en/
(Photo: Kathryn Wengel)
“I am pleased to welcome a renowned healthcare industry veteran
like Kathy to the Labcorp Board,” said Adam Schechter, chairman and
CEO of Labcorp. “Kathy brings a wealth of experience managing
complex healthcare organizations and developing globally diverse
teams. We look forward to benefitting from her unique perspective
as the Board works with management to advance Labcorp’s role in
healthcare and improving the health and lives of patients around
the world. Kathy’s appointment is also aligned with the Labcorp
Board’s commitment to bring diverse perspectives to the boardroom
that will best position us to deliver for our patients, customers,
and shareholders."
Ms. Wengel brings significant healthcare and operations
experience and global business expertise, with more than three
decades of experience in leadership positions within Johnson &
Johnson. She currently serves on Johnson & Johnson’s Executive
Committee as Executive Vice President and Chief Supply Chain
Officer. Ms. Wengel is responsible for all aspects of the
development and implementation of Johnson & Johnson’s global
Supply Chain, as well as its Quality & Compliance, Procurement,
Environmental Health and Safety, Sustainability and Engineering
& Property Services functions.
“I’ve long admired Labcorp for its innovation, leadership and
commitment to patients and their health, as most recently
demonstrated by the essential role the Company has played in
combating the COVID-19 pandemic over the last year,” said Wengel.
“I’m honored to join Labcorp’s board, and I look forward to working
with Adam and the entire Labcorp team to deliver on its important
mission and the best interests of patients, clients, and
shareholders.”
As Executive Vice President, Chief Global Supply Chain Officer,
Ms. Wengel leads a team of more than 56,000 people globally across
Johnson & Johnson’s three business segments: Pharmaceuticals,
Medical Devices and Consumer Health. Prior to this role, she served
in a variety of leadership positions with increasing
responsibilities since joining Johnson & Johnson in 1988. In
2009, she co-led the design of Johnson & Johnson’s enterprise
Supply Chain and Quality operating model and subsequently served as
the company’s first Chief Quality Officer. She also serves as an
executive sponsor for both Johnson & Johnson’s Women’s
Leadership and Inclusion Initiative and its Women in Science,
Technology, Engineering, Math, Manufacturing and Design
program.
In addition to her role at Johnson & Johnson, Ms. Wengel
serves as Chairman of the Board of GS1 Global, an organization that
sets and maintains standards regarding the exchange of critical
business data for global commerce. Ms. Wengel is also a member of
the Executive Committee of the National Association of
Manufacturers (NAM) in the US. She also serves on the Executive
Advisory Board for Gartner’s Supply Chain practice and is a member
of Supply Chain 50. In 2019, Ms. Wengel was recognized with the
Distinguished Service Award by the Council of Supply Management
Professionals (CSCMP) and was inducted into the Supply Chain Hall
of Fame.
Ms. Wengel holds a Bachelor of Science in Engineering, Civil
Engineering & Operations from Princeton University.
About Labcorp Labcorp is a leading global life sciences
company that provides vital information to help doctors, hospitals,
pharmaceutical companies, researchers, and patients make clear and
confident decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With over 70,000
employees, we serve clients in more than 100 countries. Labcorp
(NYSE: LH) reported revenue of $14 billion in FY2020. Learn about
Labcorp at www.Labcorp.com, or follow us on LinkedIn and Twitter
@Labcorp.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements, including
but not limited to statements with respect to the Company’s
leadership, future operations and opportunities for future growth.
Each of the forward-looking statements is subject to change based
on various important factors, many of which are beyond the
Company’s control, including without limitation, the performance of
executives and employees, the willingness of executives and
employees to remain employed, whether our response to the COVID-19
pandemic will prove effective, the impact of the COVID-19 pandemic
on our business and financial condition, as well as on general
economic, business, and market conditions, competitive actions and
other unforeseen changes and general uncertainties in the
marketplace, changes in government regulations, including
healthcare reform, customer purchasing decisions, including changes
in payer regulations or policies, other adverse actions of
governmental and third-party payers, the Company’s satisfaction of
regulatory and other requirements, patient safety issues, changes
in testing guidelines or recommendations, federal, state, and local
governmental responses to the COVID-19 pandemic, adverse results in
material litigation matters, failure to maintain or develop
customer relationships, our ability to develop or acquire new
products and adapt to technological changes, failure in information
technology, systems or data security, and employee relations. These
factors, in some cases, have affected and in the future (together
with other factors) could affect the Company’s ability to implement
the Company’s business strategy and actual results could differ
materially from those suggested by these forward-looking
statements. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements. The Company has
no obligation to provide any updates to these forward-looking
statements even if its expectations change. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement. Further information on potential factors,
risks and uncertainties that could affect operating and financial
results is included in the Company’s most recent Annual Report on
Form 10-K and subsequent Forms 10-Q, including in each case under
the heading RISK FACTORS, and in the Company’s other filings with
the SEC.
###
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210326005182/en/
Media: Christopher
Allman-Bradshaw — 336-436-8263 Media@Labcorp.com
Investors: Chas Cook —
336-436-5076 Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024